Spots Global Cancer Trial Database for Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer

Official Title: A Phase II Study Of Epothilone B Analogue BMS-247550 (NSC #710428) q21 Days In Advanced Carcinoma Of The Urothelium

Study ID: NCT00021099

Conditions

Distal Urethral Cancer

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter

Proximal Urethral Cancer

Recurrent Bladder Cancer

Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter

Recurrent Urethral Cancer

Regional Transitional Cell Cancer of the Renal Pelvis and Ureter

Stage III Bladder Cancer

Stage IV Bladder Cancer

Transitional Cell Carcinoma of the Bladder

Urethral Cancer Associated With Invasive Bladder Cancer

Interventions

ixabepilone

Study Description

Brief Summary: Phase II trial to study the effectiveness of ixabepilone in treating patients who have progressive or metastatic urinary tract cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

Detailed Description: OBJECTIVES: I. Determine the response rate of patients with advanced carcinoma of the urothelium treated with ixabepilone. II. Assess the toxicity of this drug in these patients. OUTLINE: Patients are stratified according to prior treatment with taxanes (yes vs no). Patients receive ixabepilone IV over 3 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 1 year.